STOCK TITAN
  1. Home
  2. Sec-filings
  3. JBIO
  4. [Form 4] Jade Biosciences, Inc. Insider Trading Activity

Jade Biosciences (JBIO) director Erin Lavelle receives 34,843-share option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jade Biosciences director Erin Lavelle received a stock option grant covering 34,843 shares of common stock. The option has an exercise price of $15.22 per share and expires on June 8, 2036. It vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to her continued service.

Positive

  • None.

Negative

  • None.
Insider Lavelle Erin
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 34,843 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 34,843 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option shares granted 34,843 shares Stock Option (Right to Buy) granted on June 9, 2026
Exercise price $15.22 per share Conversion/exercise price of stock option
Total derivative holdings after grant 34,843 options Total shares underlying options following transaction
Option expiration date June 8, 2036 Expiration of stock option
Vesting date trigger Earlier of June 9, 2027 or next annual meeting Full vesting condition subject to continued service
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 15.2200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests in full financial
"which vests in full on the earlier of (i) June 9, 2027"
annual meeting of the Issuer's stockholders financial
"the date of the next annual meeting of the Issuer's stockholders"
continued service financial
"in each case, subject to the Reporting Person's continued service to the Issuer"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lavelle Erin
(Last)(First)(Middle)
C/O JADE BIOSCIENCES, INC.
221 CRESCENT ST., BLDG. 23, STE. 105
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Jade Biosciences, Inc. [ JBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$15.2206/09/2026A34,843 (1)06/08/2036Common Stock34,843$034,843D
Explanation of Responses:
1. This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
/s/ Elizabeth Balta, as attorney-in-fact for Erin Lavelle06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Jade Biosciences (JBIO) report for Erin Lavelle?

Jade Biosciences reported that director Erin Lavelle received a grant of stock options for 34,843 shares. These options give her the right to buy common stock at a fixed price if she continues serving the company until the vesting date.

How many Jade Biosciences (JBIO) shares are covered by Erin Lavelle’s new option?

The new stock option granted to Erin Lavelle covers 34,843 shares of Jade Biosciences common stock. This figure also matches her total derivative holdings following the transaction as reported in the Form 4 filing.

What is the exercise price of Erin Lavelle’s Jade Biosciences stock option?

Erin Lavelle’s stock option has an exercise price of $15.22 per share. This means she can purchase Jade Biosciences common stock at $15.22 if the option vests and she chooses to exercise it before expiration.

When do Erin Lavelle’s Jade Biosciences stock options vest?

The options vest in full on the earlier of June 9, 2027 or the date of Jade Biosciences’ next annual stockholder meeting. Vesting is conditioned on Erin Lavelle’s continued service to the company through that time.

When do Erin Lavelle’s Jade Biosciences stock options expire?

The reported stock option for Erin Lavelle expires on June 8, 2036. She must exercise any vested portion by that date if she wishes to purchase Jade Biosciences shares at the stated exercise price.

Is Erin Lavelle’s Jade Biosciences option grant a market purchase or compensation?

The Form 4 labels the transaction as a grant or award acquisition, not a market purchase. This indicates the option was issued as part of compensation rather than bought on the open market by Erin Lavelle.